JPS63502716A - - Google Patents

Info

Publication number
JPS63502716A
JPS63502716A JP50174686A JP50174686A JPS63502716A JP S63502716 A JPS63502716 A JP S63502716A JP 50174686 A JP50174686 A JP 50174686A JP 50174686 A JP50174686 A JP 50174686A JP S63502716 A JPS63502716 A JP S63502716A
Authority
JP
Grant status
Application
Patent type
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP50174686A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
JP50174686A 1986-03-07 1986-03-07 Pending JPS63502716A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US1986/000495 WO1987005330A1 (en) 1986-03-07 1986-03-07 Method for enhancing glycoprotein stability

Publications (1)

Publication Number Publication Date
JPS63502716A true true JPS63502716A (en) 1988-10-13

Family

ID=22195409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50174686A Pending JPS63502716A (en) 1986-03-07 1986-03-07

Country Status (4)

Country Link
EP (1) EP0272253A4 (en)
JP (1) JPS63502716A (en)
DK (1) DK583087D0 (en)
WO (1) WO1987005330A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158763B2 (en) 2002-12-24 2012-04-17 Yasuhiro Kajihara Sugar chain asparagine derivatives, sugar chain asparagine, sugar chain and processes for producing these

Families Citing this family (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007641A1 (en) * 1988-02-10 1989-08-24 Genzyme Corporation Enhancement of the therapeutic properties of glycoprotein
DE3927801A1 (en) * 1989-08-23 1991-02-28 Hoechst Ag Method for the enzymatic synthesis of galactosylated glycoprotein blocks
US6319695B1 (en) * 1991-10-15 2001-11-20 The Scripps Research Insitute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
JPH07500248A (en) 1991-10-15 1995-01-12
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
DE4423131A1 (en) * 1994-07-01 1996-01-04 Bayer Ag New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
EP1500702A1 (en) 1996-04-01 2005-01-26 Genentech, Inc. APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6136958A (en) * 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
EP0942992B1 (en) 1997-01-31 2007-03-07 Genentech, Inc. O-fucosyltransferase
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP2083079A1 (en) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
CA2382409A1 (en) 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
EP1032667B1 (en) 1997-11-21 2008-10-08 Genentech, Inc. Platelet specific antigens and their pharmacological uses
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1015587B1 (en) 1997-09-18 2008-04-23 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2001522584A (en) 1997-10-10 2001-11-20 ジェネンテク・インコーポレイテッド Apo-3 ligand polypeptide
US6387657B1 (en) 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
DK1045906T3 (en) 1998-01-15 2009-02-16 Genentech Inc APO-2 ligand
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2075335A3 (en) 1998-12-22 2009-09-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO1999047677A3 (en) 1998-03-17 1999-11-11 Genentech Inc Polypeptides homologous to vegf and bmp1
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
JP2004522404A (en) 1999-12-01 2004-07-29 ジェネンテック・インコーポレーテッドGenentech,Inc. Secreted and transmembrane polypeptides and nucleic acid encoding it
EP2319929A1 (en) 1998-12-23 2011-05-11 Genentech, Inc. IL-1 related polypeptides
EP2258848B1 (en) 1999-12-23 2014-03-05 Genentech, Inc. Il-17 homologous polypeptide and therapeutic uses thereof
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR20080006002A (en) 2000-01-13 2008-01-15 제넨테크, 인크. Novel stra6 polypeptides
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6576452B1 (en) 2000-10-04 2003-06-10 Genencor International, Inc. 2,5-diketo-L-gluconic acid reductases and methods of use
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20030232334A1 (en) 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
EP2000482A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7060278B2 (en) 2001-08-29 2006-06-13 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
EP2143437B1 (en) 2001-09-18 2013-08-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
DK2279755T3 (en) 2001-10-10 2014-05-26 Ratiopharm Gmbh Glycokonjugering of remodeling and fibroblast growth factor (FGF)
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
DK2322229T3 (en) * 2001-10-10 2017-03-27 Novo Nordisk As Remodeling and glycokonjugering of Factor IX
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
WO2003046150A3 (en) 2001-11-28 2003-11-27 Neose Technologies Inc Glycoprotein remodeling using endoglycanases
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US7572763B2 (en) 2002-02-21 2009-08-11 Wyeth Follistatin domain containing proteins
JP2005535290A (en) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッドGenentech,Inc. Compositions and methods for the treatment of immune-related diseases
CA2477249A1 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
EP1501855A4 (en) 2002-03-21 2006-02-22 Sagres Discovery Inc Novel compositions and methods in cancer
JP2005536190A (en) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッドGenentech,Inc. Compositions and methods for the diagnosis and treatment of tumors
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
CA2486252C (en) 2002-06-07 2012-07-24 Genentech, Inc. Methods for screening for agents that modulate hepatocellular carcinoma development
DK1546316T3 (en) 2002-08-12 2011-02-14 Danisco Us Inc Mutant E. coli AppA phytase enzymes and natural variants thereof nucleic acids encoding such phytase enzymes, vectors and host cells incorporating same and methods of making and using these
DE60335552D1 (en) 2002-09-11 2011-02-10 Genentech Inc New composition and method for treatment of immune diseases
US20060199181A1 (en) 2002-09-11 2006-09-07 Genentch, Inc. Compositions and methods for the treatment of immune related diseases
JP2006515165A (en) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッドGenentech,Inc. New compositions and methods for the treatment of immune-related diseases
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1581169A4 (en) 2002-11-08 2008-09-17 Genentech Inc Compositions and methods for the treatment of natural killer cell related diseases
EP2308968A1 (en) 2002-11-26 2011-04-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
FR2851471B1 (en) * 2003-02-24 2006-07-28 Synt Em Compounds comprising at least one active substance and at least one subsequently assembled vector by a bonding agent, their uses and said binding agents
CN102225194B (en) 2003-03-12 2014-07-16 健泰科生物技术公司 Use of Bv8 and/or EG-VEGF to promote hematopoiesis
ES2420581T3 (en) 2003-03-14 2013-08-26 Biogenerix Gmbh water soluble polymers branched and their conjugates
CA2518371A1 (en) 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2004103275A3 (en) 2003-05-09 2007-05-18 Neose Technologies Inc Compositions and methods for the preparation of human growth hormone glycosylation mutants
CA2526085A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005019258A3 (en) 2003-08-11 2006-04-13 Genentech Inc Compositions and methods for the treatment of immune related diseases
EP2327723A3 (en) 2003-10-10 2012-06-27 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EP2412725A3 (en) 2003-11-17 2012-04-25 Genentech, Inc. Antibodies against CD79b for the treatment of tumor of hematopoeitic origin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
ES2445948T3 (en) 2003-11-24 2014-03-06 Ratiopharm Gmbh erythropoietin glicopegilada
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
ES2560657T3 (en) 2004-01-08 2016-02-22 Ratiopharm Gmbh O-linked glycosylation of peptides G-CSF
ES2403055T3 (en) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anti-P-selectin
KR20070008645A (en) 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 O-linked glycoforms of polypeptides and method to manufacture them
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
JP2008507288A (en) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII receptor polypeptides, methods, and compositions
WO2006031811A3 (en) 2004-09-10 2006-09-21 Henrik Clausen Glycopegylated interferon alpha
JP5948627B2 (en) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー Remodeling and carbohydrate pegylated of fibroblast growth factor (fgf)
WO2006053301A3 (en) 2004-11-12 2007-04-05 Xencor Inc Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006071441A3 (en) 2004-11-30 2007-02-22 Curagen Corp Antibodies directed to gpnmb and uses thereof
US9820986B2 (en) 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5047947B2 (en) 2005-05-05 2012-10-10 デューク ユニバーシティ Anti-cd19 antibody treatment for autoimmune disease
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー/エス Glycopegylated first ix factor
JP2008541781A (en) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッドGenentech,Inc. Their use for the characterization of transgenic animals, and genes for different genes
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
ES2357626T3 (en) 2005-08-24 2011-04-28 The Rockefeller University Lysines mutants PLY-GBS.
WO2007056191A3 (en) 2005-11-03 2007-10-25 Neose Technologies Inc Nucleotide sugar purification using membranes
KR101557375B1 (en) 2005-11-23 2015-10-08 악셀레론 파마 인코포레이티드 Their use for activin solution to promote bone growth and antagonists -actrⅱa
JP2009527227A (en) 2006-02-17 2009-07-30 ジェネンテック・インコーポレーテッドGenentech,Inc. Gene disruption, compositions and methods related thereto
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008036437A3 (en) 2006-04-19 2008-10-02 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2420252A1 (en) 2006-08-04 2012-02-22 Novartis AG EPHB3-specific antibody and uses thereof
ES2444065T3 (en) 2006-08-18 2014-02-24 Novartis Ag PRLR-specific antibody and uses thereof
CN101516914A (en) 2006-09-29 2009-08-26 霍夫曼-拉罗奇有限公司 Antibodies against CCR5 and uses thereof
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As Methods for the purification of polypeptide conjugates
RU2460543C2 (en) 2006-10-04 2012-09-10 Ново Нордиск А/С Glycerol linked pegylated sugars and glycopeptides
KR101581961B1 (en) 2006-11-02 2016-01-04 악셀레론 파마 인코포레이티드 Alk1 and receptor ligands antagonists and their use
KR20090105913A (en) 2006-11-02 2009-10-07 다니엘 제이 카폰 Hybrid immunoglobulins with moving parts
KR101672156B1 (en) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 Activin-actriia antagonists and uses for promoting bone growth in cancer patients
KR101508397B1 (en) 2007-02-22 2015-04-08 제넨테크, 인크. Methods for detecting inflammatory bowel disease
US9050304B2 (en) 2007-04-03 2015-06-09 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
CN101861168B (en) 2007-05-07 2014-07-02 米迪缪尼有限公司 Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ES2551123T3 (en) 2007-06-12 2015-11-16 Ratiopharm Gmbh Improved process for the production of nucleotide sugars
EP2167534B1 (en) 2007-07-12 2012-07-04 Compugen Ltd. Bioactive peptides and method of using same
EP2657253B1 (en) 2008-01-31 2017-07-19 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009032845A3 (en) 2007-09-04 2009-05-28 Copugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
CA2711826C (en) 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use
RU2573587C2 (en) 2008-02-27 2016-01-20 Ново Нордиск А/С Conjugated factor viii molecules
EP2294087B1 (en) 2008-05-01 2014-05-14 Amgen, Inc. Anti-hepcidin antibodies and methods of use
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
CN103641907A (en) 2008-06-17 2014-03-19 印第安纳大学研究及科技有限公司 Glucagon/glp-1 receptor co-agonists
CA2729296A1 (en) 2008-06-17 2010-01-28 Richard D. Dimarchi Gip-based mixed agonists for treatment of metabolic disorders and obesity
CA2727161A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CN105535938A (en) 2009-08-13 2016-05-04 阿塞勒隆制药公司 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
WO2010040766A1 (en) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
CA2742899A1 (en) 2008-11-06 2010-05-14 Glenmark Pharmaceuticals, S.A. Treatment with anti-alpha2 integrin antibodies
JP5933975B2 (en) 2008-11-12 2016-06-15 メディミューン,エルエルシー Antibody preparation
CN102300874B (en) 2008-12-08 2015-08-05 卡姆普根有限公司 Tmem154 polypeptides and polynucleotides and their use as pharmaceutical and biological products to produce a target for drug
CN102245624B (en) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 Based on insulin prodrug amide
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
US9102731B2 (en) 2008-12-23 2015-08-11 Amgen Inc. Human CGRP receptor binding proteins
CA2752647A1 (en) 2009-02-24 2010-09-02 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
US20120064096A1 (en) 2009-03-17 2012-03-15 Universite De La Mediterranee BTLA Antibodies and Uses Thereof
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US8563513B2 (en) 2009-03-27 2013-10-22 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
CA2757095A1 (en) 2009-03-30 2010-10-07 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
US8580732B2 (en) 2009-04-07 2013-11-12 Duke University Peptide therapy for hyperglycemia
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
WO2010144452A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20110070233A1 (en) 2009-09-09 2011-03-24 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JP6016636B2 (en) 2009-10-15 2016-10-26 ジェネンテック, インコーポレイテッド Chimeric fibroblast growth factor with the modified receptor specificity
RU2539772C2 (en) 2009-10-22 2015-01-27 Дженентек, Инк. Methods and compositions for hepsin modulation of macrophage-stimulating protein
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
US20120208762A1 (en) 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
EP3260130A3 (en) 2009-11-03 2018-02-07 Acceleron Pharma Inc. Methods for treating fatty liver disease
ES2658292T3 (en) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses thereof with respect to the induction of utrophin for the treatment of muscular dystrophy
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
EP2507265B1 (en) 2009-12-01 2016-05-11 Compugen Ltd. Antibody specific for heparanase splice variant T5 and its use.
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2011097527A3 (en) 2010-02-04 2012-01-26 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
WO2011104604A3 (en) 2010-02-23 2011-12-01 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
WO2011160062A3 (en) 2010-06-17 2012-03-15 Actogenix Nv Compositions and methods for treating inflammatory conditions
WO2011163012A3 (en) 2010-06-24 2013-07-11 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
EP2585102B1 (en) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
CA2805024A1 (en) 2010-06-30 2012-01-05 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiples sclerosis, rheumatoid arthritis and other autoimmune disorders
EP2596025B1 (en) 2010-07-23 2018-06-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
JP5953303B2 (en) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド Antibodies having isoelectric points that have been modified
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
CN103458920B (en) 2010-12-22 2016-07-06 印第安那大学科技研究公司 Gip exhibiting pancreatic glucagon receptor activity analog
DK2654789T3 (en) 2010-12-22 2018-09-03 Orega Biotech Antibodies to human CD39 and their use
WO2012090150A3 (en) 2010-12-27 2012-11-01 Compugen Ltd New cell-penetrating peptides and uses thereof
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
CN103517922B (en) 2011-03-31 2016-10-19 国家医疗保健研究所 The use of antibodies and anti icos
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CN108341863A (en) 2011-04-20 2018-07-31 阿塞勒隆制药公司 Endoglin polypeptides and uses thereof
KR20140041572A (en) 2011-05-19 2014-04-04 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Anti-human-her3 antibodies and uses thereof
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
JP6179864B2 (en) 2011-06-22 2017-08-16 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Glucagon / glp-1 Reseputako - agonist
CA2836855A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Medicale) Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Medicale) Antibodies for the treatment and prevention of thrombosis
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Medicale) Antibodies for the treatment and prevention of thrombosis
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
WO2013052933A3 (en) 2011-10-06 2013-09-12 The Board Of Trustees Of The University Of Illinois Myosin binding protein- c for use in methods relating to diastolic heart failure
RU2014117678A (en) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon superfamily peptides having glucocorticoid receptor activity
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
US20150045301A1 (en) 2011-12-16 2015-02-12 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
KR20140126357A (en) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 antibodies, and uses thereof for treatment of cancer
WO2013136193A8 (en) 2012-03-16 2014-05-08 University Health Network Methods and compositions for modulating toso activity
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP2847219A1 (en) 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin antibodies
EP2861259A1 (en) 2012-06-14 2015-04-22 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
KR20150023013A (en) 2012-06-21 2015-03-04 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon analogs exhibiting gip receptor activity
EP2864355B1 (en) 2012-06-25 2016-10-12 Orega Biotech Il-17 antagonist antibodies
WO2014004549A3 (en) 2012-06-27 2014-03-13 Amgen Inc. Anti-mesothelin binding proteins
ES2684552T3 (en) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale ICOS antibodies directed against the disease to treat graft versus host
CN105452295A (en) 2012-12-10 2016-03-30 比奥根Ma公司 Anti-blood dendritic cell antigen 2 antibodies and uses thereof
KR20150100848A (en) 2012-12-27 2015-09-02 사노피 Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
KR20150129685A (en) 2013-03-15 2015-11-20 젠코어 인코포레이티드 Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2948478A1 (en) 2013-01-25 2015-12-02 Amgen Inc. Antibodies targeting cdh19 for melanoma
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US20140271629A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
CN105263514A (en) 2013-03-15 2016-01-20 本质生命科学有限公司 Anti-hepcidin antibodies and uses thereof
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US20160122436A1 (en) 2013-03-15 2016-05-05 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP3036320A1 (en) 2013-08-19 2016-06-29 Biogen MA Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
WO2015066557A1 (en) 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Therapeutic nuclease molecules with altered glycosylation and methods
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
WO2015127134A3 (en) 2014-02-20 2015-11-05 Allergan, Inc. Complement component c5 antibodies
FR3020063A1 (en) 2014-04-16 2015-10-23 Gamamabs Pharma anti-human antibody HER4
US20170037148A1 (en) 2014-04-16 2017-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
WO2016040767A3 (en) 2014-09-12 2016-04-28 Amgen Inc. Chrdl-1 epitopes and antibodies
US20170247471A1 (en) 2014-09-30 2017-08-31 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
US20170327861A1 (en) 2014-10-17 2017-11-16 Biogen Ma Inc. Copper Supplementation for Control of Glycosylation in Mammalian Cell Culture Process
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
US20170327786A1 (en) 2014-10-31 2017-11-16 Biogen Ma Inc. Hypotaurine, GABA, Beta-Alanine, and Choline for Control of Waste Byproduct Accumulation in Mammalian Cell Culture Process
US20160355608A1 (en) 2014-11-26 2016-12-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US20160237399A1 (en) 2015-02-18 2016-08-18 Biogen Ma Inc. Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
US20170037131A1 (en) 2015-03-05 2017-02-09 Matthew Bernett Modulation of t cells with bispecific antibodies and fc fusions
CN108136001A (en) 2015-04-03 2018-06-08 佐马技术有限公司 Treatment of cancer using inhibitors of tgf-beta and pd-1
JP2018512151A (en) 2016-05-04 2018-05-17 アムジエン・インコーポレーテツド Interleukin-2 mutein for the proliferation of regulatory t cells
WO2016166360A1 (en) 2015-04-17 2016-10-20 Bayer Pharma Aktiengesellschaft Bispecific antibody constructs for cdh3 and cd3
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
EP3322733A1 (en) 2015-07-13 2018-05-23 Compugen Ltd. Hide1 compositions and methods
WO2017066561A3 (en) 2015-10-16 2017-06-08 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017182427A1 (en) 2016-04-19 2017-10-26 Amgen Research (Munich) Gmbh Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
WO2018005954A3 (en) 2016-07-01 2018-03-29 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
WO2018013917A1 (en) 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
WO2018064098A1 (en) 2016-09-28 2018-04-05 Cohbar, Inc. Therapeutic mots-c related peptides
WO2018064255A3 (en) 2016-09-28 2018-06-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
US20180127487A1 (en) 2016-10-20 2018-05-10 Sanofi Anti-chikv antibodies and uses thereof
WO2018156892A1 (en) 2017-02-23 2018-08-30 Adrx, Inc. Peptide inhibitors of transcription factor aggregation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847890A (en) * 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF BIOLOGICAL CHEMISTRY=1977 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158763B2 (en) 2002-12-24 2012-04-17 Yasuhiro Kajihara Sugar chain asparagine derivatives, sugar chain asparagine, sugar chain and processes for producing these

Also Published As

Publication number Publication date Type
WO1987005330A1 (en) 1987-09-11 application
DK583087A (en) 1987-11-06 application
EP0272253A1 (en) 1988-06-29 application
EP0272253A4 (en) 1990-02-05 application
DK583087D0 (en) 1987-11-06 grant

Similar Documents

Publication Publication Date Title
DE3738376C2 (en)
DE8613317U1 (en)
DE8600592U1 (en)
DE8601499U1 (en)
JPH0247850Y2 (en)
DE8605764U1 (en)
DE8700306U1 (en)
DE8705038U1 (en)
DE8616935U1 (en)
DE8620206U1 (en)
DE8613315U1 (en)
DE8621044U1 (en)
JPH01501052A (en)
JPH0211301Y2 (en)
JPH0123638B2 (en)
DE8632470U1 (en)
DE8605632U1 (en)
JPH0132397Y2 (en)
JPH0137917Y2 (en)
JPH0141173Y2 (en)
JPH0142743Y2 (en)
DE8609148U1 (en)
DE8632615U1 (en)
DE8608895U1 (en)
JPH0247585Y2 (en)